Other formats:
BibTeX
LaTeX
RIS
@article{1173781,
author = {Šváchová, Hana and Kryukov, Fedor and Kryukova, Elena Vladimirovna and Ševčíková, Sabina and Němec, Pavel and Grešliková, Henrieta and Říhová, Lucie and Kubiczková, Lenka and Hájek, Roman},
article_location = {England},
article_number = {5},
doi = {http://dx.doi.org/10.1111/bjh.12689},
keywords = {nestin; multiple myeloma; monoclonal gammopathy; stem cells; flow cytometry},
language = {eng},
issn = {0007-1048},
journal = {British journal of haematology},
note = {+ projekt 7. rámce FP7/2007-2013 No. 278570},
title = {Nestin expression throughout multistep pathogenesis of multiple myeloma},
volume = {164},
year = {2014}
}
TY - JOUR
ID - 1173781
AU - Šváchová, Hana - Kryukov, Fedor - Kryukova, Elena Vladimirovna - Ševčíková, Sabina - Němec, Pavel - Grešliková, Henrieta - Říhová, Lucie - Kubiczková, Lenka - Hájek, Roman
PY - 2014
TI - Nestin expression throughout multistep pathogenesis of multiple myeloma
JF - British journal of haematology
VL - 164
IS - 5
SP - 701-709
EP - 701-709
PB - Wiley-Blackwell
SN - 00071048
N1 - + projekt 7. rámce FP7/2007-2013 No. 278570
KW - nestin
KW - multiple myeloma
KW - monoclonal gammopathy
KW - stem cells
KW - flow cytometry
N2 - The stem cell marker nestin (NES) is found in dividing cells of developing and regenerating tissues. Upon terminal differentiation, NES expression is diminished but may be re-expressed following injury or in cancer. Surprisingly, we recently confirmed NES as a tumour-specific marker for mature CD138(+)38(+) plasma cells (PC) in multiple myeloma (MM). The present study analysed NES expression throughout the spectrum of MM developmental stages, starting with individuals with no haematological malignancy, through monoclonal gammopathy of undetermined significance (MGUS) and MM to plasma cell leukaemia (PCL) and MM cell lines. NES was analysed in bone marrow PC of 163 MM, four PCL and nine MGUS patients, 10 individuals with no haematological malignancy and 6 myeloma cell lines (OPM-2, RPMI-8226, MOLP-8, U-266, EJM, NCI-H929) by flow cytometry and/or real-time polymerase chain reaction or immunochemistry. We observed a tendency of increased NES expression in parallel with disease progression. NES was evaluated as a reliable marker for accurate discrimination between MM patients and the control group. High NES levels were strongly associated with the presence of 1q21 gain. For the first time, NES was demonstrated to predict worse response to conventional therapy/novel agents. These results suggest that NES might become a useful clinical parameter with an important role in MM pathogenesis.
ER -
ŠVÁCHOVÁ, Hana, Fedor KRYUKOV, Elena Vladimirovna KRYUKOVA, Sabina ŠEVČÍKOVÁ, Pavel NĚMEC, Henrieta GREŠLIKOVÁ, Lucie ŘÍHOVÁ, Lenka KUBICZKOVÁ and Roman HÁJEK. Nestin expression throughout multistep pathogenesis of multiple myeloma. \textit{British journal of haematology}. England: Wiley-Blackwell, 2014, vol.~164, No~5, p.~701-709. ISSN~0007-1048. Available from: https://dx.doi.org/10.1111/bjh.12689.
|
